Glenmark gains on getting tentative nod for Gabapentin Enacarbil Extended-Release Tablets, Apremilast Tablets

31 Dec 2020 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 501.50, up by 2.75 points or 0.55% from its previous closing of Rs. 498.75 on the BSE.

The scrip opened at Rs. 500.00 and has touched a high and low of Rs. 507.35 and Rs. 497.35 respectively. So far 40871 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.70 on 22-Jun-2020 and a 52 week low of Rs. 168.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 507.35 and Rs. 491.75 respectively. The current market cap of the company is Rs. 14277.71 crore.

The promoters holding in the company stood at 46.63%, while Institutions and Non-Institutions held 30.25% and 23.13% respectively.

Glenmark Pharmaceuticals has received tentative approval by the United States Food & Drug Administration (USFDA) for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg, the generic version of Horizant Extended-Release Tablets, 300 mg and 600 mg, of Arbor Pharmaceuticals, LLC. The Horizant market achieved annual sales of approximately $99.5 million.

Additionally, the company has received tentative approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg, the generic version of Otezla Tablets, 10 mg, 20 mg and 30 mg, of Amgen, Inc. The Otezla Tablets, 10 mg, 20 mg and 30 mg market achieved annual sales of approximately $2.7 billion.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1028.50 -12.25 (-1.18%)
23-Apr-2024 11:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1521.25
Dr. Reddys Lab 6030.65
Cipla 1363.55
Zydus Lifesciences 951.80
Lupin 1594.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.